Jansitin Duo

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jansitin Duo, are a biguanide and a DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adult patients by improving blood glucose control. The combination targets both hepatic glucose output and incretin‑mediated insulin secretion, offering a complementary approach to glycemic management.

GNH USA supplies Jansitin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑origin products that meet stringent quality and regulatory standards.

Jansitin Duo combines metformin and sitagliptin to address hyperglycemia in type 2 diabetes through complementary mechanisms.

- Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. - Inadequate control with metformin alone: provides additional glucose‑lowering effect to achieve target HbA1c. - Combination therapy with DPP‑4 inhibitors: offers an oral alternative to insulin for patients requiring intensified treatment. - Adjunct to lifestyle modification: supports weight‑neutral management in patients where weight gain is a concern.

Like all antidiabetic agents, Jansitin Duo may be associated with adverse reactions.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Headache

Serious or Rare Side Effects: - Lactic acidosis - Acute pancreatitis

Before prescribing Jansitin Duo, clinicians should consider several safety factors.

- Renal function: assess creatinine clearance before initiating and periodically monitor. - Hepatic function: avoid in patients with significant liver disease due to lactic acidosis risk. - Cardiovascular status: use cautiously in heart failure, especially NYHA class III/IV. - Concomitant hypoglycemics: monitor for enhanced hypoglycemia when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Jansitin Duo may interact with several medicines; awareness helps prevent complications.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin temporarily. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase sitagliptin exposure, raising risk of adverse effects. - Insulin secretagogues (e.g., sulfonylureas): potentiate hypoglycemia when combined.

Moderate Interactions (Monitor Closely): - Diuretics (especially thiazides): may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Warfarin: sitagliptin may alter INR; check coagulation parameters. - Alcohol: can increase risk of lactic acidosis with metformin.